Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: STOML2

Gene summary for STOML2

Gene summary.

Gene information	Species	Human
	Gene symbol	STOML2
	Gene ID	30968
	Gene name	stomatin like 2
	Gene Alias	HSPC108
	Cytomap	9p13.3
	Gene Type	protein-coding
	GO ID	GO:0001775
	UniProtAcc	Q9UJZ1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
30968	STOML2	GSM4909281	Human	Breast	IDC	4.34e-09	3.78e-01	0.21
30968	STOML2	GSM4909282	Human	Breast	IDC	1.61e-38	6.86e-01	-0.0288
30968	STOML2	GSM4909285	Human	Breast	IDC	6.64e-19	4.19e-01	0.21
30968	STOML2	GSM4909288	Human	Breast	IDC	3.62e-09	4.12e-01	0.0988
30968	STOML2	GSM4909290	Human	Breast	IDC	2.28e-09	4.83e-01	0.2096
30968	STOML2	GSM4909292	Human	Breast	IDC	6.33e-10	7.66e-01	0.1236
30968	STOML2	GSM4909293	Human	Breast	IDC	5.19e-04	2.61e-01	0.1581
30968	STOML2	GSM4909296	Human	Breast	IDC	7.03e-11	8.27e-02	0.1524
30968	STOML2	GSM4909297	Human	Breast	IDC	1.70e-14	-7.85e-02	0.1517
30968	STOML2	GSM4909304	Human	Breast	IDC	3.72e-07	3.50e-01	0.1636
30968	STOML2	GSM4909311	Human	Breast	IDC	2.73e-25	-2.03e-01	0.1534
30968	STOML2	GSM4909312	Human	Breast	IDC	1.40e-08	5.91e-02	0.1552
30968	STOML2	GSM4909316	Human	Breast	IDC	3.61e-04	2.39e-03	0.21
30968	STOML2	GSM4909319	Human	Breast	IDC	3.17e-39	-8.15e-02	0.1563
30968	STOML2	GSM4909320	Human	Breast	IDC	4.24e-07	-3.95e-03	0.1575
30968	STOML2	GSM4909321	Human	Breast	IDC	3.41e-12	-8.52e-02	0.1559
30968	STOML2	brca1	Human	Breast	Precancer	9.20e-09	3.94e-01	-0.0338
30968	STOML2	brca2	Human	Breast	Precancer	3.19e-05	2.65e-01	-0.024
30968	STOML2	brca3	Human	Breast	Precancer	6.80e-04	2.79e-01	-0.0263
30968	STOML2	NCCBC14	Human	Breast	DCIS	3.36e-06	-1.56e-01	0.2021

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001598012	Liver	Cirrhotic	energy derivation by oxidation of organic compounds	154/4634	318/18723	3.11e-20	8.87e-18	154
GO:00061197	Liver	Cirrhotic	oxidative phosphorylation	86/4634	141/18723	6.08e-20	1.66e-17	86
GO:00068397	Liver	Cirrhotic	mitochondrial transport	112/4634	254/18723	1.03e-11	6.66e-10	112
GO:000675312	Liver	Cirrhotic	nucleoside phosphate metabolic process	190/4634	497/18723	1.10e-11	6.96e-10	190
GO:000911712	Liver	Cirrhotic	nucleotide metabolic process	187/4634	489/18723	1.55e-11	9.63e-10	187
GO:001969312	Liver	Cirrhotic	ribose phosphate metabolic process	156/4634	396/18723	5.83e-11	3.23e-09	156
GO:000925912	Liver	Cirrhotic	ribonucleotide metabolic process	151/4634	385/18723	1.72e-10	8.70e-09	151
GO:00516046	Liver	Cirrhotic	protein maturation	121/4634	294/18723	3.54e-10	1.68e-08	121
GO:007252112	Liver	Cirrhotic	purine-containing compound metabolic process	156/4634	416/18723	3.74e-09	1.52e-07	156
GO:000915012	Liver	Cirrhotic	purine ribonucleotide metabolic process	141/4634	368/18723	4.22e-09	1.70e-07	141
GO:000616312	Liver	Cirrhotic	purine nucleotide metabolic process	146/4634	396/18723	4.12e-08	1.34e-06	146
GO:001921611	Liver	Cirrhotic	regulation of lipid metabolic process	119/4634	331/18723	3.05e-06	5.39e-05	119
GO:00164853	Liver	Cirrhotic	protein processing	85/4634	225/18723	9.01e-06	1.32e-04	85
GO:001087611	Liver	Cirrhotic	lipid localization	147/4634	448/18723	6.24e-05	7.12e-04	147
GO:00463905	Liver	Cirrhotic	ribose phosphate biosynthetic process	71/4634	190/18723	7.09e-05	7.98e-04	71
GO:00092605	Liver	Cirrhotic	ribonucleotide biosynthetic process	68/4634	182/18723	1.00e-04	1.05e-03	68
GO:00091654	Liver	Cirrhotic	nucleotide biosynthetic process	89/4634	254/18723	1.45e-04	1.40e-03	89
GO:19012934	Liver	Cirrhotic	nucleoside phosphate biosynthetic process	89/4634	256/18723	1.97e-04	1.82e-03	89
GO:00091526	Liver	Cirrhotic	purine ribonucleotide biosynthetic process	62/4634	169/18723	3.52e-04	3.00e-03	62
GO:19905425	Liver	Cirrhotic	mitochondrial transmembrane transport	41/4634	102/18723	4.08e-04	3.37e-03	41

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

STOML2

insertion

In_Frame_Ins

novel

c.869_870insTGGGGA

p.Ala290_Lys291insGlyAsp

p.A290_K291insGD

Q9UJZ1

protein_coding

TCGA-BH-A0H7-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

STOML2

insertion

In_Frame_Ins

novel

c.868_869insAGCTGGGCTTGGCCAGGGAGT

p.Ala290delinsGluLeuGlyLeuAlaArgGluSer

p.A290delinsELGLARES

Q9UJZ1

protein_coding

TCGA-BH-A0H7-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

STOML2

SNV

Missense_Mutation

rs763483882

c.215G>A

p.Arg72Gln

p.R72Q

Q9UJZ1

protein_coding

tolerated(0.09)

benign(0.094)

TCGA-EA-A3HS-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

STOML2

SNV

Missense_Mutation

rs753222022

c.511N>T

p.Arg171Cys

p.R171C

Q9UJZ1

protein_coding

deleterious(0.01)

possibly_damaging(0.892)

TCGA-AA-3966-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

STOML2

SNV

Missense_Mutation

rs201944176

c.776G>A

p.Arg259Gln

p.R259Q

Q9UJZ1

protein_coding

tolerated(0.48)

benign(0.003)

TCGA-AA-A00N-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

STOML2

SNV

Missense_Mutation

c.1062G>T

p.Lys354Asn

p.K354N

Q9UJZ1

protein_coding

deleterious_low_confidence(0.01)

benign(0.003)

TCGA-G4-6303-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Chemotherapy

5-fu

STOML2

SNV

Missense_Mutation

c.445N>A

p.Glu149Lys

p.E149K

Q9UJZ1

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-G4-6304-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Chemotherapy

fluorouracil

STOML2

SNV

Missense_Mutation

novel

c.628N>T

p.Thr210Ser

p.T210S

Q9UJZ1

protein_coding

tolerated(0.36)

benign(0.098)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

STOML2

SNV

Missense_Mutation

rs781632715

c.512N>A

p.Arg171His

p.R171H

Q9UJZ1

protein_coding

tolerated(0.1)

possibly_damaging(0.806)

TCGA-AJ-A3EK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

STOML2

SNV

Missense_Mutation

rs201944176

c.776N>A

p.Arg259Gln

p.R259Q

Q9UJZ1

protein_coding

tolerated(0.48)

benign(0.003)

TCGA-AJ-A5DW-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1